Company
Headquarters: Tokyo, Japan
Employees: 90
CEO: Mr. Masato Tsumamoto
¥10.24 Billion
JPY as of Jan. 1, 2026
US$65.4 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
CellSource Co. Ltd has the following listings and related stock indices.
Stock: JPX: 4880 wb_incandescent